The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 5, 2017-08 ,pp. : 624-633

Bentham Science Publishers

Access to resources Recommend Favorite

Dose Sparing of CpG Oligodeoxynucleotide Vaccine Adjuvants by Nanoparticle Delivery

By  

Current Drug Delivery, Vol. 1, Iss. 4, 2004-10 ,pp. : 405-412

Bentham Science Publishers

Access to resources Recommend Favorite

A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases

By Gupta Kaveri  

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens

By  

Current Drug Delivery, Vol. 6, Iss. 1, 2009-01 ,pp. : 76-82

Bentham Science Publishers

Access to resources Recommend Favorite

The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN

By Raney Sameersingh   Wilson Kaley   Sekirov Laura   Chikh Ghania   de Jong Susan   Cullis Pieter   Tam Ying  

Journal of Drug Targeting, Vol. 16, Iss. 7-8, 2008-08 ,pp. : 564-577

Informa Healthcare

Access to resources Recommend Favorite